A tiny implant might fix a leaky heart valve without cutting open the chest

NCT ID NCT04679662

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early feasibility study tests a new device called the PLAR Implant, designed to treat severe degenerative mitral regurgitation—a condition where the heart's mitral valve doesn't close properly, causing blood to leak backward. The implant is delivered through a vein in the leg and guided to the heart, aiming to tighten the valve's support ring. The study will enroll up to 10 patients at high surgical risk and will follow them for five years to see if the procedure is safe and can reduce the severity of the leak.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PLAR Implant and Delivery System (a device for transcatheter mitral valve repair)
What this could lead to
If successful, this could offer a less invasive treatment option for people with severe degenerative mitral regurgitation who are at high risk for open-heart surgery.
What could go wrong
This is a very early, small study (up to 10 patients) focused on safety and feasibility, not proof of effectiveness. The procedure carries risks such as bleeding, infection, or device-related complications, and results may not apply to a broader population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEGENERATIVE MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • InCor - Instituto do Coração do Hospital das Clínicas da FMUSP

    São Paulo, São Paulo, 05403-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.